NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products designed to treat Major Depressive Disorder and other diseases of the Central Nervous System (e.g. Autism, Parkinson's Disease, Anxiety, Post Traumatic Stress Disorder, etc.). The Company is led by experienced medical device executives and entrepreneurs.
Headquartered in Boston, MA, NeoSync is privately held.
Lawrence C. Best, Chairman
Larry joined Boston Scientific Corporation starting in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. Formerly serving on the Board of Directors of Haemonetics Corp, Larry is currently chairman of OXO Capital LLC, serves on the Board of Directors of Myriad Genetics (NASDAQ:MYGN), and is a founding director of the President's Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.
Kate Rumrill, President & CEO
Kate brings 27 years experience in the Medical Device and Pharmaceutical Industry. Previously she held the position of Vice President, Global Clinical & Medical Affairs at Covidien. She has extensive experience in product development in the CNS space through her time at Aspect Medical Systems and Eli Lilly & Company. Kate first joined NeoSync in 2010, leading the company’s clinical and regulatory activities, and later rejoined as President & CEO in April 2015. She holds a BS degree in both Biology and Psychology from the State University of New York.
Paul Kravitz, Director, Clinical Research
Paul brings 15 years of Medical Device industry clinical research and R&D experience. Prior to joining NeoSync in 2017, he spent the past decade in the renal space working on home therapies with NxStage Medical. His career also includes time in the fields of diabetes with Abbott Laboratories and endoscopic surgery with Smith & Nephew. Paul holds a BS degree in Biochemistry from Tufts University.
Leo Basta, Regulatory Affairs
Leo was a co-founder of Boston Biomedical Associates (BBA), a consulting firm that provides a full range of regulatory, quality assurance, and clinical research services to medical device and biomedical companies. At BBA, Leo was responsible for directing all consulting services for Regulatory Affairs and Quality Assurance. Leo has over 25 years of experience from the medical device, in-vitro diagnostic, and pharmaceutical industries. Prior to founding BBA, Leo had a 13-year career with Boston Scientific Corporation (BSC), a multi-billion dollar corporation and major manufacturer of innovative medical devices.
Paul Manberg, PhD, Clinical/Regulatory Strategy
Dr. Manberg has over 35 years of experience managing the regulatory and clinical development programs for a wide range medical device and pharmaceutical products. He has designed and executed numerous US and international multicenter clinical trials leading to successful product registrations and market adoption activities and held executive positions at Ares-Serono, Aspect Medical Systems, and Covidien. Dr. Manberg currently serves as a strategic clinical and regulatory consultant for a number of early-stage medical device companies. He received his Bachelor’s degree in Biology from SUNY-Binghamton and his PhD in Pharmacology from the University of North Carolina, School of Medicine.
Paula Rebucci, Quality
Paula has been a Quality professional in the Medical Device field for the last 30 years. She began her career with United States Surgical Corporation which was eventually sold to Tyco International before spinning off into Covidien. Throughout her career, she held a number of leadership roles in the areas of Quality Engineering, New Product Development and Quality Operations. For the last 17 years she had been the Management Representative for a number of Covidien facilities. She has expertise in Class II and III Medical devices and Class III combination devices. As the Management representative, Paula has successfully hosted over 75 audits from the FDA, ISO representing bodies, PMDA, JPAL, ANVISA, MDD, CMDR and a number of individual countries. Quality systems, CAPA and process improvements are Paula strengths. She is certified in LEAN Manufacturing and is a certified Black Belt Champion successfully mentoring 9 of her employees to Black Belt status. Paula received her BS degree from Western Connecticut State University.
Chandran Seshigiri, PhD, Algorithm/EEG processing
Dr. Seshigiri,possesses extensive experience with bio potential signals, signal processes and algorithm development. He has held a variety of positions in Med Device research, including development and commercialization of novel EEG-based algorithms. Notably, he was an instrumental member of the Aspect Medical Systems/Covidien neuroscience research team. More recently, he has been working as an independent scientific consultant for a variety of companies, including NeoSync. Dr. Seshigiri holds a Bachelors of Arts in Physics from Rice University and a PhD from Massachusetts Institute of Technology, where he focused on neuronal characteristics in the brain.
David Zraket, R&D Engineering
David has more than 25 years of medical device experience. His primary focus has been in product development, clinical research engineering support, and technology education. As one of the founders of Aspect Medical Systems, David has a deep expertise in EEG waveforms and EEG based technologies. David holds a BS in Biomedical engineering from Duke University and Masters in Nuclear Engineering from Massachusetts Institute of Technology.